Table 1.
Population characteristics
| Parameter | Median (IQR) | N (%) |
|---|---|---|
| Age, years | 52 (46–56) | |
| BMI, kg/m2 | 22.8 (20.9–25.4) | |
| Time since HIV diagnosis, years | 18 (11–23) | |
| Prior cART exposure, years | 15 (10–20) | |
| Prior PI exposure, years | 5 (0–9) | |
| Prior TDF exposure, years | 5 (3–7) | |
| CD4+ T-cell nadir, cells/µL | 168 (108–295) | |
| Current CD4+ T-cells, cells/µL | 622 (460–860) | |
| Hgb, g/dL | 14.3 (13.6–15.3) | |
| Platelets ×1,000/µL | 208 (172–245) | |
| ALT, U/L | 23 (16–33) | |
| AST, U/L | 22 (18–31) | |
| HDL cholesterol, mg/dL | 50 (40–62) | |
| LDL cholesterol, mg/dL | 115 (95–147) | |
| Serum creatinine, mg/dL | 0.8 (0.7–1.0) | |
| e-GFR (CKD-EPI), mL/min/1.73 m2 | 89.3 (76.9–103.5) | |
| VACS index | 16 (6–23) | |
| Sex, male | 107 (67.7) | |
| HBV coinfection | 6 (3.9) | |
| HCV coinfection | 39 (25.2) | |
| Current cART: | ||
| PI-based | 52 (32.9) | |
| NNRTI-based | 71 (44.9) | |
| INI-based | 35 (22.2) | |
| NRTI in the regimen: | ||
| None | 34 (21.9) | |
| 3TC only | 3 (1.9) | |
| TDF only | 3 (1.9) | |
| ABC+3TC | 44 (28.4) | |
| TDF+FTC | 71 45.8) | |
| HIV disease stage: | ||
| CDC-A | 55 (36.2) | |
| CDC-B | 55 (36.2) | |
| CDC-C | 42 (27.6) | |
| Lumbar mineralization status: | ||
| Normal | 66 (53.7) | |
| Osteopenia | 44 (35.8) | |
| Osteoporosis | 13 (10.6) | |
| Femoral mineralization status: | ||
| Normal | 56 (45.2) | |
| Osteopenia | 57 (46.0) | |
| Osteoporosis | 11 (8.9) |
Abbreviations: ABC, abacavir; BMI, body mass index; cART, combined antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; e-GFR, estimated glomerular filtration rate; FTC, emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; HDL, high-density lipoproteins; Hgb, hemoglobin; HIV, human immunodeficiency virus; INI, integrase inhibitor; IQR, interquartile range; LDL, low-density lipoprotein; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir difumarate; VACS, Veterans Aging Cohort Study; 3TC, lamivudine.